Inovio Pharmaceuticals
INO
Conference date: November 10, 2026 @ 1:30 PM Pacific Time
for quarter ending: September 30, 2026 (Q3, third quarter)

Forward-looking statements
Overview: Voceryq (INO-3107) for RRP approved by FDA
Basic data (GAAP):
Revenue was $299 thousand, up sequentially from $0 thousand, and up from $0 million in the year-earlier quarter.
Net income was negative $49.2 million, down sequentially from negative $6.0 million, and down from negative $45.5 million year-earlier.
EPS (earnings per share, diluted) was negative $0.50, down sequentially from negative $0.07, but up from negative $0.87 year-earlier due to increased share count.
Guidance:
Cash should last until late Q4 2027.
Quarter Highlights:
Dr. Jacqueline [Jackie] Shea, Inovio's CEO said, "We are delighted with the recent approval of Voceryq, which FDA described as a groundbreaking therapy that fights RRP at its source, not only its symptoms. Inovio is now a commercial stage company with a primary goal to establish Voceryq as the preferred first-line immunotherapy for RRP patients. Our recently completed public offering provides additional financial resources to support a successful launch. Furthermore, this approval validates our DNA medicine platform and we are actively seeking partnerships to accelerate the development of other exciting candidates within our pipeline."
Believes about 25,000 US adults with RRP. Expects relatively rapid approvals by Payers, about 80% of patients within 9 months. Most RRP patients are treated by one of about 400 laryngologists. Hopes to expand Voceryq to younger patients and international markets.
On October 30, 2026 FDA approved Voceryq (INO-3107) for RRP (Recurrent Respiratory Papillomatosis) including the Cellectra 5PSP device component. Accelerated, Conditional approval, so must also start the Phase 3 trial. Should be available for ordering around January 1, 2027. [WM: Will compete with Precigen's Papzimeos, which was approved in 2025, but which may require scoping and a surgery during administration. The trials were not identical, nor were the labels, so there is room for salespeople to argue.]
In Q4 Inovio presented nonclinical (mouse) data highlighting the potential of its next-generation DNA-Encoded Protein (DPROT) programs at the Soft Bones Third International Meeting on Hypophosphatasia (HPP).
Given the recent validation of its DNA technology, Inovio is continuing discussions with potential partners to accelerate development of this promising platform with a focus on developing additional DPROT indications in rare diseases, including Hemophilia A, Fabry Disease and HPP.
In May 2026 ApolloBio, the China partners, reported positive Phase 3 data for VGX-3100 for cervical dysplasia. Results planned for use for filing for China. There is potential for Inovio to receive regulatory and sales-based milestone payments.
Inovio also has a variety of other vaccines in clinical or preclinical study. See the Inovio Pipeline for an overview.
Cash and equivalents balance ended at $48.4 million, up sequentially from $36.7 million. In Q3 (July) raised $18.3 million in another public equity offering. After the quarter ended, and the therapy approval, raised another $80.5 million from stock sales and $11 million from exercising of warrants. No debt, but $70 million in common stock warrant liabilities.
Q4 2024 R&D expense was $10.6 million. General and administrative expense was $9.2 million. Total operating expenses were $19.8 million. Operating profit negative $19.5 million. Interest $0.3 million. Change in fair value of stock warrant liability negative $27 million. Other expense $3.2 million.
Q&A selective summary:
Launch v. Pazimeos? They have seen strong uptake, we see that as showing medical need. They have only reached a small fraction of RRP so far. We believe Voceryq will appeal and become the first line therapy because it does not require scoping and surgery during the dosing procedure.
Durability improvement in 2nd year? It was solid in second year and durable in third year. Statistically and clinically meaningful.
Europe plans, including partner? Looking for ex-US partners. Submission of marketing authorization in EU will support that. Conversations before the application were positive for EU. Looking beyond that.
There are some nations that accept FDA approvals, but they typically don't have the resources for a product like Voceryq.
We think our plasmid and DPROT programs are now very attractive to potential partners. Key areas are our late stage pipeline canidates, and the protein replacement therapies.
Physicians trained so far? Only the original 8 clinical trial sites so far. 20 sites in preparing for confirmatory study. Training can be done in 30 minutes, need product and patients first. Field team, by end of Q1 2027, should cover 90% of potential patients.
OpenIcon
Analyst Conference Summaries Main Page |